What we do
Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability.
Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.
Who we are - History
Making biologics available & affordable to all through technology innovation
KEY FIGURES
- 2013 Incorporation Date
- 5 companies 1 Group with 4 affiliates
- 15.000.000m2 New offices in Jumet
- 350+ Dedicated people
Latest News
Univercells strengthens Board with Appoi…
Univercells S.A. (“Univercells”) management and Board of Directors, reached an agreement today with Timothy E. Morris to present him for off…
Univercells to present at the 40th Annua…
Hugues Bultot, CEO of Univercells Group, will present on Thursday, January 13 at 13.30 CET (7.30 a.m. ET). The presentation will be a live a…
Univercells acquires SynHelix, entering…
Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutic…
Univercells and Unizima announce Hala Au…
Univercells S.A. (“Univercells”) and Unizima S.A. (“the Company”), announce today the appointment of Hala Audi as Chief Executive Officer of…